National Cancer Institute: Clinical Trials Information for Patients and Caregivers
Patient Education: Dexamethasaone (Decadron) and other Steroids
Patient Education: Selinexor (Xpovio) - XPO1 inhibitor
Dana-Farber's 2022 Multiple Myeloma Patient Symposium - Update on Multiple Myeloma Treatment
You are central to the care team: Be Empowered - IMF Patient & Family Webinar - May 14, 2022
PE: CDC Guidelines: How to prevent infections (Sepsis) while getting chemotherapy?
Patient Education: Bortezomib (Velcade) - Proteasome Inhibitor
Patient Education: Carfilzomib (Kyprolis) - Proteasome Inhibitor
Patient Education: Ixazomib (Ninlaro) - Proteasome Inhibitor
Siteman Cancer Center: Autologous stem cell transplant at Siteman Cancer Center
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
How to Prevent Neutropenic Sepsis on Treatment? Know Your ANC (Absolute Neutrophil Count)
MPE survey on myeloma and AL amyloidosis diagnosis
IMF - International Myeloma Foundation: Patient Handbook 2022
Patient Education: Thalidomide (Thalomid) Immunomodulatory Agents - IMIDS
Patient Education: Revlimid (lenalidomide) - Immunomodulatory Agents - IMIDS
What is Multiple Myeloma? www.uptodate.com
Patient Education: Pomalidomide (Pomalyst) Immunomodulatory Agents - IMIDS
The Binding Site: Freelite Overview
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy
Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy
